Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and Valbenazine
Authors:
Open Access
- 18 December 2022
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 12 (4) , 447-456
Abstract
Valbenazine and deutetrabenazine are vesicular monoamine transporter 2 (VMAT2) inhibitors approved for tardive dyskinesia. The clinical activity of valbenazine is primarily attributed to its only dihydrotetrabenazine (HTBZ) metabolite, [+]‐α‐HTBZ. Deutetrabenazine is a deuterated form of tetrabenazine and is metabolized to four deuterated HTBZ metabolites: [+]‐α‐deuHTBZ, [+]‐β‐deuHTBZ, [−]‐α‐deuHTBZ, and [−]‐β‐deuHTBZ. An open‐label, crossover study characterized the pharmacokinetic profiles of the individual deuHBTZ metabolites, which have not been previously reported. VMAT2 inhibition and off‐target interactions of the deuHTBZ metabolites were evaluated using radioligand binding. The only valbenazine HTBZ metabolite, [+]‐α‐HTBZ, was a potent VMAT2 inhibitor, with negligible affinity for off‐target dopamine, serotonin, and adrenergic receptors. Following deutetrabenazine administration, [−]‐α‐deuHTBZ represented 66% of circulating deuHTBZ metabolites and was a relatively weak VMAT2 inhibitor with appreciable affinity for dopamine (D2S, D3) and serotonin (5‐HT1A, 5‐HT2B, 5‐HT7) receptors. [+]‐β‐deuHTBZ was the most abundant deuHTBZ metabolite that potently inhibited VMAT2, but it represented only 29% of total circulating deuHTBZ metabolites. The mean half‐life of [+]‐α‐HTBZ (22.2 hours) was ∼3× longer than that of [+]‐β‐deuHTBZ (7.7 hours). These findings are similar to studies with tetrabenazine, in that deutetrabenazine is metabolized to four deuHTBZ stereoisomers, the most abundant of which has negligible interaction with VMAT2 in vitro and appreciable affinity for several off‐target receptors. In contrast, valbenazine's single HTBZ metabolite is a potent VMAT2 inhibitor in vitro with no discernible off‐target activity. Determination of the effects of intrinsic/extrinsic variables on deutetrabenazine's safety/efficacy profile should incorporate assessment of the effects on all deuHTBZ metabolites.Keywords
This publication has 30 references indexed in Scilit:
- Systematic Overview of Warfarin and Its Drug and Food InteractionsArchives of internal medicine (1960), 2005
- A novel class of 5-HT2a receptor antagonists: Aryl aminoguanidinesLife Sciences, 1996
- The human serotonin 5‐HT2B receptor: Pharmacological link between 5‐HT2 and 5‐HT1D receptorsFEBS Letters, 1994
- Further characterization of human α2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugsEuropean Journal of Pharmacology, 1994
- Characterization of the human dopamine D3 receptor expressed in transfected cell linesEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Cloning and expression of human and rat Dt dopamine receptorsNature, 1990
- Binding of [3H]dihydrotetrabenazine and [125I]azidoiodoketanserin photoaffinity labeling of the monoamine transporter of platelet 5-HT organellesEuropean Journal of Pharmacology, 1990
- Cloning of the cDNA and gene for a human D2 dopamine receptor.Proceedings of the National Academy of Sciences, 1989
- [3H]RX821002: a new tool for the identification of α2A-adrenoceptorsEuropean Journal of Pharmacology, 1989
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973